Clinical trials: Mood
Major Depression
Lexapro and Pramipexole and to Treat Major Depression
This study compares the effectiveness of the combination of antidepressants: Lexapro and Pramipexole, with the effectiveness of each antidepressant alone.
- Trial name
- NCT00086307
- Testing
- Pramipexole, Escitalopram
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder, Metabolic Syndrome
Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder
The proposed study is a non-randomized, open label trial that will examine the potential to reduce metabolic risk factors in patients with bipolar I disorder and improve psychiatric and functional outcomes.
- Trial name
- NCT00665444
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pittsburgh
Insomnia, Bipolar Disorder
Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder
The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder.
- Trial name
- NCT02527564
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Stanford University
Major Depressive Disorder
miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome
The purpose of this study is to examine whether neural-derived exosomal miRNAs are differentially expressed that are specific to suicidal ideation or behavior, and which by affecting specific miRNA targets and pathways, are…
- Trial name
- NCT02418195
- Testing
- ketamine
- Where
- United States
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Major Depressive Disorder
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
- Trial name
- NCT02972632
- Testing
- Vortioxetine
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Takeda
Pulmonary Disease, Chronic Obstructive, Major Depression
Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Approximately 20% of patients with chronic obstructive pulmonary disease (COPD) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity.
- Trial name
- NCT00151372
- Testing
- Treatment Adherence Intervention, Enhanced Care
- Where
- 3 sites in United States
- Volunteers
- 141 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Stress and the Sympathetic Nervous System in Adults With Depression
To test our hypotheses, we will enroll healthy adults having no history of mood disorders and adults with major depressive disorder (MDD) having a broad range of depressive symptom severity.
- Trial name
- NCT04838262
- Testing
- Acute Stressors
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Mental Disorders, Severe, Schizophrenia and Related Disorders
A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses
Insufficient community-based support after inpatient discharge for persons with serious mental illnesses (SMI) may lead to re-hospitalization, excessive criminal justice involvement, homelessness, and an inability to embrace…
- Conditions
- Mental Disorders, Severe, Schizophrenia and Related Disorders, Bipolar Disorder, Depressive Disorder
- Trial name
- ODR (NCT04612777)
- Testing
- Opening Doors to Recovery, Case Management, Intensive Case Management
- Volunteers
- 240 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major
Zelquistinel in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
- Trial name
- AGN-241751 (NCT03586427)
- Testing
- AGN-241751
- Where
- 25 sites in United States
- Volunteers
- 251 people
- Sponsor
- Syndeio Biosciences, Inc
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Cigarette Smoking, Drug Use
Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment
The objective of the proposed project is to develop a novel, behavioral approach to smoking cessation that can be integrated with residential drug use treatment for low income substance using smokers with elevated depressive…
- Trial name
- BA-DAS (NCT01372254)
- Testing
- Standard Treatment, BAD-AS, Transdermal Nicotine Patch
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Maryland, College Park
Major Depressive Disorder
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.
- Trial name
- NCT03864614
- Testing
- SAGE-217
- Where
- 52 sites in United States
- Volunteers
- 1,515 people
- Sponsor
- Biogen
Perimenopausal Depression
Perimenopausal Effects of Estradiol on Reward Responsiveness
Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women either with or without depression.
- Trial name
- PEERS (NCT02255175)
- Testing
- Estradiol, Progesterone
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Bipolar Disorder
An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients
This study is planned to objectively assess the efficacy and safety of lamotrigine maintenance therapy after symptoms of mood episode had been stabilised by open-label treatment with lamotrigine alone or in combination with other…
- Trial name
- NCT00550407
- Testing
- lamotrigine
- Where
- 60 sites in Japan
- Volunteers
- 215 people
- Sponsor
- GlaxoSmithKline
Mood
Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation
Clomiphene citrate is commonly used for ovulation induction in women with anovulation, correction of luteal phase deficiency or for superovulation as empiric therapy for unexplained infertility.
- Trial name
- NCT01291056
- Testing
- Clomiphene
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Utah
Bipolar Disorder
Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
- Trial name
- NCT00257166
- Testing
- Ziprasidone oral capsules
- Where
- 50 sites in United States
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Menopausal Depression
Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women
This protocol is a controlled study of estradiol therapy in early postmenopausal women with and without frequent hot flashes that will be used to determine whether hot flashes are an important intermediary in the generation of…
- Trial name
- NCT01126801
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.